Protalix BioTherapeutics Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Protalix BioTherapeutics stock.
View analyst ratings for Protalix BioTherapeutics or view top-rated stocks.

Wall Street analysts have given Protalix BioTherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Protalix BioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Protalix BioTherapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 2,470,000 shares, an increase of 18.2% from the June 30th total of 2,090,000 shares. Based on an average daily trading volume, of 2,250,000 shares, the short-interest ratio is currently 1.1 days. Currently, 7.1% of the company's shares are sold short.
View Protalix BioTherapeutics' Short Interest.

Protalix BioTherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Protalix BioTherapeutics.

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) issued its quarterly earnings data on Thursday, May, 13th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.03. The business earned $11.32 million during the quarter, compared to analyst estimates of $10.95 million.
View Protalix BioTherapeutics' earnings history.

Protalix BioTherapeutics's stock reverse split before market open on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix BioTherapeutics stock prior to the reverse split would have 10 shares after the split.

1 equities research analysts have issued 1 year target prices for Protalix BioTherapeutics' shares. Their forecasts range from $7.00 to $7.00. On average, they expect Protalix BioTherapeutics' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 363.6% from the stock's current price.
View analysts' price targets for Protalix BioTherapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Protalix BioTherapeutics include Eiger BioPharmaceuticals (EIGR), Innate Pharma (IPHA), Surface Oncology (SURF), Jounce Therapeutics (JNCE), Innate Pharma (IPHYF), INmune Bio (INMB), Aptose Biosciences (APTO), Achilles Therapeutics (ACHL), Tscan Therapeutics (TCRX), Adverum Biotechnologies (ADVM), Miromatrix Medical (MIRO), Cardiff Oncology (CRDF), ADMA Biologics (ADMA), Elevation Oncology (ELEV) and Cabaletta Bio (CABA).
View all of PLX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Novavax (NVAX), BioLineRx (BLRX), VBI Vaccines (VBIV), Sangamo Therapeutics (SGMO), Verastem (VSTM), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP).

Protalix BioTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Protalix BioTherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own Protalix BioTherapeutics stock include Aharon Schwartz and Pharma Technologies Ltd Dexcel.
View institutional ownership trends for Protalix BioTherapeutics.

PLX stock was purchased by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Protalix BioTherapeutics or or view top insider-buying stocks.

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PLX stock can currently be purchased for approximately $1.51.

Protalix BioTherapeutics has a market capitalization of $68.52 million and generates $62.90 million in revenue each year. The company earns $-6,520,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

Protalix BioTherapeutics employs 207 workers across the globe.

The official website for Protalix BioTherapeutics is www.protalix.com.

Protalix BioTherapeutics is headquartered at 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel.

Protalix BioTherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100 or via email at [email protected]